|
|
|
| The Immunological Character of Polypeptide B Cell Epitopes Vaccines of Alzheimer's Disease in Different Adjuvants |
| CHEN Ao1,2, YU Yun-zhou1, WANG Wen-bin1, PANG Xiao-bin2, WANG Shuang1, YU Wei-yuan1, SUN Zhi-wei1 |
1. Institute of Biotechnology,Academy of Military Medical Sciences,Beijing 100071,China;
2. Pharmaceutical College of Henan University,Kaifeng 475001,China |
|
|
|
Abstract Objective:To evaluate the immune response of polypeptide vaccines Aβ1-15-PADRE(Aβ-T)against Alzheimer's disease containing the immunodominant B cell epitope from β-amyloid and pan-DR helper T cell epitopes and determine whether various adjuvants could boost the efficacy or performance of the vaccine in mouse model. Methods:The polypeptides of 2Aβ1-15-PADRE containing two B cell epitopes Aβ1-15 and one pan-DR helper T cell epitope PADRE was be artificially synthesized as polypeptide vaccines Aβ1-15-PADRE. Compared to the PBS control or untreated control,the immunogenicity of polypeptide vaccines without adjuvant and with four different adjuvants(Aluminum,Freund's adjuvant,MF59 adjuvant and Abisco adjuvant respectively)were evaluated in Balb/C mouse model. Results:All groups produced the specific antibody IgG against Aβ. But the four adjuvant groups were better to generate immune response than Mock group or negative control. Of these,the titer of antibodies produced by the Freund's adjuvant group was highest. The results of dot blotting showed that the sera antibodies could bind to the oligomer of Aβ better than the monomer form. But the antibodies have not binding reaction to the fiber form. Conclusion:All of these adjuvants could enhance the effect of polypeptide vaccine against Alzheimer's disease in mouse model. All of the sera antibodies bind to the oligomer form of Aβ. The immunological character shows that the polypeptide vaccine is potential in clinical trial.
|
|
Received: 31 December 2010
Published: 25 August 2011
|
|
|
|
|
|
[1] Schenk D,Barbour R,Dunn W,et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature,1999,400:173-177.
[2] Wilcock D M,Colton C A. Anti-Aβ immunotherapy in Alzheimer's disease;relevance of transgenic mouse studies to clinical trials. Alzheimer's Disease,2008,15(4):555-569.
[3] Singh H,Raghava G P. Propred:prediction of HLA-DR binding sites. Bioinformatics,2001,17(12):1236-1237.
[4] Agadjanyan M G,Ghochikyan A,Petrushina I,et al. Prototype Alzheimer's disease vaccine using the immunodominat B cell epitope from beta-amyloid and promiscuous T cell pan HLA DR-binding peptide. Immunol,2005,174:1580-1586.
[5] Petrushina I,Ghochikyan A,Mktrichyan M,et al. Alzheimer's disease peptide vaccine reduces insoluble but not soluble/olimeric Aβ species in Amyloid precursor protein transgenic mice. The Journal of Neuroscience,2007,27:12721-12731.
[6] Hardy J A,Higgins G A,Alzheimer's disease:the amyloid cascade hypothesis. Science,1992,256:184-185.
[7] Klein W L,Krafft G A,Finch C E,Targeting small Abeta oligomers:the solution to an Alzheimer's disease conundrum? Trends Neurosci,2001,24:219-224.
[8] Glabe C C. Amyloid accumulation and pathogensis of Alzheimer's disease:significance of monomeric,oligomeric and fibrillar Abeta. Subcell Biochem,2005,38:167-177.
[9] Walsh D M,Selkoe D J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron,2004,44:181-193.
[10] Sanjay W Pimplikar. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol,2009, 41(6):1261-1268.
[11] Bacskai B J,Kajdasz S T,Christie R H,et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med,2001,7:369-372.
[12] Frenkel D,Solomon B,Benhar I. Modulation of Alzheimer's beta-amyloid neurotoxicity by sitedirected single-chain antibody. Neuroimmunol,2000,106(1-2):23-31.
[13] Bard F,Cannon C,Barbour R,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med,2000,6:916-919.
[14] Bacskai B J,Kajdasz S T,Mclellan M E,et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci,2002,22:7873-7878.
[15] Demottos R B,Bales K R,Cummins D J,et al. Brain to plasma amyloid-betefflux:a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science,2002,295:2264-2267.
[16] Schultzea V,D’Agostob V,Wackc A,et al. Safety of MF59 adjuvant. Vaccine,2008,26:3209-3222.
[17] Lambert M P,Viola K L,Chromy B A,et al. Vaccination with soluble Ab oligomers generates toxicity-neutralizing antibodies. Journal of Neurochemistry,2001,79,595-605.
[18] Cribbs D H,Ghochikyan A,Vasilevko V,et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. International Immunology,2003,15:505-514.
[19] Waller A,Flock M,Smith K,et al. Vaccination of horses against strangles using recombinant antigens from Streptococcus equi. Vaccine,2007,25:3629-3635.
[20] Pellegrini M, Nicolayb U,Lindertc K,et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines:Integrated analysis from a large safety database. Vaccine,2009,27:6959-6965.
[21] Morgan D,Diamond D M,Gottschall P E,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature,2001,408:982-985.
[22] Janus C,Pearson J,McLaurin J,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature,2000,408:979-982.
[23] Walsh D M,Klyubin I,Shankar G M,et al. The role of cell-derived oligomers of Aβ in Alzheimer's disease and avenues for therapeutic intervention. Biochemical Society,2005,1087-1090.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
